Major

Inclusion Criteria:

1. Histological evidence of MM and evidence of relapse or refractory disease. Patients
with non secretory myeloma or plasmacytoma only will be excluded.

2. Patients must have failed thalidomide, lenalidomide, or velcade or be intolerant or
ineligible to receive these agents.

3. Age ≥18 years.

4. ECOG performance status 0-2.

5. Patients must have adequate organ and marrow function

Major Exclusion Criteria:

1. Prior cytotoxic chemotherapy or investigational agent within 28 days or autologous
stem cell transplant within 6 months of receiving study drug ENMD-2076.

2. Prior radiation therapy to > 25% of bone marrow forming bones (i.e., pelvis).

3. Concomitant corticosteroid therapy in doses greater than 10 mg daily of prednisone
(or equivalent) if given for management of co-morbid conditions.

4. Have unstable angina pectoris or recent myocardial infarction (within 6 months.

5. Have uncontrolled hypertension or congestive heart failure.